Dear Editor: The selective serotonin reuptake inhibitors (SSRIs) are used to treat a wide array of psychiatric conditions (1) . Patients experience fewer side effects, compared with the older antidepressants (2) . However, sexual dysfunction may occur in up to 75% of patients taking antidepressants (3) . I report a case in which a patient taking sertraline experienced decreased to almost nonexistent erections, with a return to his baseline functioning following treatment with vardenafil. To my knowledge, this is the first reported case of vardenafil used to treat antidepressantinduced sexual dysfunction.
Mr A, aged 32 years, was diagnosed with dysthymic disorder according to DSM-IV criteria. He was in good health and did not use alcohol, tobacco, or illicit substances. He had been married for 6 years and described his marriage as excellent. He was active in psychotherapy and referred for medication. He agreed to a trial of sertraline started at 50 mg dialy and titrated to 150 mg at 3 weeks' time. I obtained a baseline sexual history prior to his starting the sertraline and informed him that the medication could affect his sexual functioning. Mr A stated that he understood and agreed to a trial. Within 2 weeks of initiating sertraline, he began to notice diminished erections but no change in libido. Although he was discouraged about this side effect, he had noted an improvement in his dysthymic symptoms and desired to remain on sertraline. He was interested in adding bupropion sustained release (SR) in an attempt to improve sexual functioning. He began bupropion SR 100 mg daily with no improvement at 1 week, and the dosage was increased to 150 mg daily, with no success after 1 week. The bupropion SR was increased to 200 mg daily; again, there was no success at the end of 1 week, and it was discontinued. A trial of vardenafil 10 mg taken 30 minutes prior to sexual activity was initiated, with noted improvement within 3 days of initiation. Mr A has on occasion taken it 15 minutes prior to sexual activity, with positive results. The patient tolerated the medication without any noted side effects. Mr A has returned to his baseline sexual functioning and is fully satisfied with the quality of his erections.
As noted, a baseline sexual functioning history was taken prior to initiating treatment with sertraline, and the patient was informed about the possibility of sexual dysfunction. These factors facilitated discussion of this commonly occurring problem in patients treated with antidepressants. Taking this history also allows clinicians to distinguish between an antidepressant side effect or a preexisting condition that can occur in up to 31% of men (4) . Clinicians frequently are called upon to manage sexual dysfunction as a result of antidepressants. According to a recent survey by Dording and others, 43% of psychiatrists add bupropion to existing medication (5) . Bupropion SR has been shown to be beneficial at dosages between 100 and 200 mg taken once daily, with most improvement noted within the first 2 weeks of treatment (6) . My patient did not benefit from this strategy and required an alternate agent. I chose vardenafil, a new a phosphodiesterase 5 (PDE5) inhibitor, on the basis of work by Fava and others (7) and Nurnberg and others (8) . These authors successfully treated patients suffering from antidepressant-induced sexual dysfunction with sildenafil, a PDE5 inhibitor. Vardenafil is a highly selective PDE5 inhibitor used to treat erectile dysfunction (9) . It is generally well tolerated and significantly enhances sexual functioning (10) . Improvement in other aspects of sexual functioning, including confidence, orgasmic functions, and satisfaction, were noted in a recent review of vardenafil (11) . Although my patient experienced the successful return of his pretreatment sexual functioning, caution is advised when interpreting case report results. Vardenafil may be valuable in expanding treatment options for clinicians managing the common side effect of antidepressant-induced sexual dysfunction, but further controlled studies will be needed.
Tim Berigan, MD Vail, Arizona

Reconsidering Pimozide for New-Onset Delusions of Parasitosis
Dear Editor: For the last few decades, pimozide has been the standard therapy for delusional parasitosis. However, the latest evidence suggests that the newer atypical antipsychotics should be first-line therapy, owing to their better side effect profile and greater efficacy (1) (2) (3) (4) (5) (6) .
We report the case of a patient with new-onset delusional parasitosis who was begun on olanzepine but whose symptoms resolved with pimozide.
Case Report
Mr W, a white man aged 41 years, presented to emergency after experiencing tactile and visual hallucinations for 3 weeks. He described a "chain-saw worm," a "shark bug," and beetles poking their eyes out of his fingernails and boring holes into the skin of his arms, legs, and penis. To help decrease further infestation, he showered for 2 hours and prepared his bed for 6 hours daily.
His medical history is complex but not progressive, including chronic ankylosing spondylitis, Crohn's disease, and hepatitis C. He has a history of child abuse and treated chronic depression. He had an episode of postoperative delirium but no other prior psychotic symptoms. His 9 daily medications included prednisone, ranitidine, sertraline, and high dosages of morphine.
Because of its deliriogenic effects, Mr W's morphine was decreased from 360 mg daily to 300 mg daily. He was begun on olanzepine 2.5 mg daily, which was increased to 10 mg daily within 3 days. He remained on the higher dosage of olanzepine for 1 week with no change in his symptoms or agitation. At this point, he met the "1-month" criteria for delusional disorder, somatic type. He was switched to pimozide 2 mg daily. Within 10 days, complete resolution of his symptoms occurred. He was discharged home on pimozide, which was tapered to 1 mg after 1 month. At 6 weeks, he had no recurrent symptoms. The pimozide will be discontinued at 2 months.
Discussion
Pimozide therapy was first reported to be beneficial for somatic delusions in 5 patients in 1975 (7) . Several small, noncontrolled studies have reported its benefits, which include recovery from delusions of parasitosis in up to 90% of patients (1) .
Newer studies suggest that atypical antipsychotics are equally effective (2) . The serotonergic activity of atypicals is suggested to have the additional benefit of reducing the obsessive-compulsive and self-mutilatory features of somatic delusions (2) .
Case reports have found response to risperidone in various somatic delusional disorders (4) (5) (6) . In a 1997 study, treatment with risperidone eliminated symptoms in 3 patients with long histories of delusions of parasitosis who did not respond to haloperidol or pimozide (3) . Recently, treatment with low-dosage olanzapine led to complete resolution of symptoms in a case of delusions of infestation (8) . Most patients in these studies presented with long-standing histories, having experienced delusions for months to years.
In our case, the older, typical neuroleptic pimozide was effective in treating the newonset delusion of infestation. More rigorous study into the benefits of treatment with pimozide vs the newer neuroleptics would be useful, not only for treating somatic delusions but also for patients presenting with early symptoms.
Gabapentin Treatment for Premature Ejaculation
Dear Editor: Premature or rapid ejaculation (PE) is the commonest sexual dysfunction in men, with a reported prevalence of up to 39% in the general male population and an even greater prevalence in the first-degree male relatives of men with PE (1). The essential feature of PE is persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and before the person wishes it (2) . However, no standardized method of assessing PE has been defined, and research criteria have included the following measures: reduced latency to ejaculation after intromission or reduced intravaginal latency time (IELT), limited control over the occurrence of ejaculation, concern about ejaculating too soon, dissatisfaction with the inability to select the moment of ejaculation, and the occurrence of antiportal ejaculation.
PE is postulated to be a neurobiological phenomenon involving primarily a disturbance of serotonin 5-HT 2C and 5-HT 1A receptor function. However, ejaculation in male humans is a complex physiological process: other central inputs and neurotransmitters, such as dopamine, and autonomic and somatic reflexes dependent on alpha 1-adrenergic and cholinergic neurons, respectively , all play a role (1).
Consequently, numerous medications known to influence different receptors are reported to delay ejaculation. These include serotonergic drugs such as selective serotonin reuptake inhibitors (SSRIs) and clomipramine, alpha-adrenergic antagonists such as prazosin, and benzodiazepines such as clonazepam (3) . I report the successful use of gabapentin, an anticonvulsant, in the treatment of PE.
Case Report
Mr X, aged 40 years, has a DSM-IV diagnosis of PE, lifelong situational type attributable to combined factors. Stop-pause, stop-squeeze coital alignment techniques and the use of a condom with topical anesthetic (5% lidocaine) were associated with limited response. Conventional pharmacotherapies were also minimally effective and had doselimiting side effects. Treatment with paroxetine, sertraline, and to a lesser extent, venlafaxine was associated with restless legs, gastrointestinal disturbance, headache, decreased libido, and erectile dysfunction. Trazodone and lorazepam caused sedation and cognitive slowing, while bupropion accelerated ejaculation. Mr X had previously found that alcohol produced satisfactory ejaculatory delay with no loss of erectile capacity, but clearly this was not a feasible regular option. A trial of gabapentin 300 mg taken 1 to 2 hours prior to intercourse resulted in a similar effect with no side effects. Higher doses of 600 mg resulted in further retardation of ejaculation but also in somnolence.
The mechanism of action of gabapentin is not clear, but it is believed to increase GABA through increased GABA release and synthesis and to decrease the release of monoamine neurotransmitters (4). Since benzodiazepines and alcohol can also delay ejaculation and are also GABAergic through a direct action on GABA-A receptors, it is postulated that gabapentin's effect on ejaculation may be mediated via its action on GABA. Further, anorgasmia has been described in a male patient with bipolar disorder receiving gabapentin (5) .
Currently, there are no specific treatments for PE, although dapoxetine, an SSRI-type drug with a short half-life, is undergoing clinical trials. Thus, gabapentin merits further consideration, particularly in those men for whom other therapies are ineffective or poorly tolerated.
